API | pruvanserin

pruvanserin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW

Pruvanserin is a selective 5-HT2A receptor antagonist which was under development by Eli Lilly and Company for the treatment of insomnia. It was in phase II clinical trials in 2008 but appears to have been discontinued as it is no longer in the company's development pipeline. In addition to its sleep-improving properties, pruvanserin has also been shown to have antidepressant, anxiolytic, and working memory-enhancing effects in animal studies. ^Wikipedia

Chemistry

SMILES: N#Cc1c[nH]c2c(C(=O)N3CCN(CCc4ccc(F)cc4)CC3)cccc12
InChIKey: AQRLDDAFYYAIJP-UHFFFAOYSA-N
Mol. Mass: 376.44
ALogP: 3.18 Partition coefficient
ChEMBL Molecule:
pruvanserin

More Chemistry

Pharmacology

Mechanism of Action:
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

emd-281014 | emd-390920 | lsn-2422347 | ly2422347 | ly-2422347 | pruvanserin

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)

Sleep Initiation and Maintenance Disorders (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 1
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue